CENTOGENE News & Events Header Image Broschure


Stay up to date and read about our most recent milestones towards achieving CENTOGENE’s mission: To enable the cure of 100 rare diseases in 10 years.

Interested in receiving the latest news around the clock? Follow us on LinkedIn.

Supporting Patients for Accelerated Diagnosis and Treatment Development

Cambridge, MA USA & Rostock, Germany December 13, 2019 - In an update…

Cambridge, MA USA & Rostock, Germany December 6, 2019 – CENTOGENE (Nasdaq: CNTG) today announced the expansion of its executive leadership team with…

ROSTOCK/BERLIN, Deutschland und CAMBRIDGE, MA, USA 21. November 2019 (GLOBE NEWSWIRE) - CENTOGENE (Nasdaq: CNTG), ein auf seltene Erkrankungen…

CAMBRIDGE, Mass. and ROSTOCK and BERLIN, Germany, November 21, 2019 (GLOBE NEWSWIRE) – CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on…

Focus on Aromatic L-amino Acid Decarboxylase (AADC) Deficiency

Accelerating new rare disease therapies through collaboration agreement

Global award honors entrepreneurship, innovation, and personal commitment

Supporting rare disease diagnosis, education, and clinical research

Driving Accelerated Diagnosis and Treatment Development

Driving personalized, immune-based therapy to target patients’ own immune responses

For Further Inquiries Please Contact

Press Contact

Ben Legg

Corporate Communications

Email Us


Here you can find forms, brochures, flyer and information sheets for download (PDF) about the broad genetic testing product and service portfolio of CENTOGENE.